


## Proglumide sodium

Cat. No.:	HY-103354
CAS No.:	99247-33-3
Molecular Formula:	C <sub>18</sub> H <sub>25</sub> N <sub>2</sub> NaO <sub>4</sub>
Molecular Weight:	356.39
Target:	Cholecystokinin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



### SOLVENT & SOLUBILITY

In Vitro	H <sub>2</sub> O : 100 mg/mL (280.59 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.8059 mL	14.0296 mL	28.0591 mL
				5 mM	0.5612 mL	2.8059 mL	5.6118 mL
				10 mM	0.2806 mL	1.4030 mL	2.8059 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (280.59 mM); Clear solution; Need ultrasonic						

### BIOLOGICAL ACTIVITY

Description	Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK's effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities <sup>[1][2][3][4][5]</sup> .
IC <sub>50</sub> & Target	Cholecystokinin (CCK)-A/B receptors <sup>[1][2]</sup>
In Vitro	In an in vitro study, Proglumide at concentrations between 0.3-10 mM inhibits CCK-stimulated amylase release dose-dependently, while Proglumide does not influence the basal amylase release at concentrations between 0-3 mM. Dose-response curves to CCK for amylase release shifted to the right with increase in Proglumide concentration. This inhibition by Proglumide is reversible. In addition, the effect of Proglumide is selective for CCK and its related peptide <sup>[2]</sup> . The incubation of HT29 cells with Proglumide significantly reduces the [ <sup>3</sup> H]-thymidine incorporation to HT29 cells in a dose-dependent manner, with an IC <sub>50</sub> of 6.5 mM. Proglumide reduces in a dose-dependent manner the percentage of necrosis with a parallel increase of apoptosis up to 70% <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**

Proglumide (250-750 mg/kg; intraperitoneal injection; adult male Sprague Dawley rats) treatment is significantly effective in ameliorating the seizure activities, cognitive dysfunctions, and cerebral oxidative stress<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Sprague Dawley rats (200-250 g; 2 months old) are induced status epilepticus (SE) <sup>[1]</sup>
Dosage:	250 mg/kg, 500 mg/kg, and 750 mg/kg
Administration:	Intraperitoneal injection
Result:	Dose-dependently and significantly increased the latencies to seizure and SE. Significantly and dose-dependently attenuated Li-PC (SE) induced increase in thiobarbituric acid (TBARS) and catalase (CAT), attenuated Li-Pc induced decrease in SOD, and attenuated depletion of GSH and glutathione-S transferase (GST) in the hippocampus and striatum.

**REFERENCES**

- [1]. Ahmad M, et al. The effects of quinacrine, proglumide, and pentoxifylline on seizure activity, cognitive deficit, and oxidative stress in rat lithium-pilocarpine model of status epilepticus. *Oxid Med Cell Longev*. 2014;2014:630509.
- [2]. Iwamoto Y, et al. In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini. *Gastroenterol Jpn*. 1984 Feb;19(1):53-8.
- [3]. González-Puga C, et al. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. *J Pineal Res*. 2005 Oct;39(3):243-50.
- [4]. Bunney BS, et al. Further studies on the specificity of proglumide as a selective cholecystokinin antagonist in the central nervous system. *Ann N Y Acad Sci*. 1985;448:345-51.
- [5]. Tariq M, et al. Gastric and duodenal antiulcer and cytoprotective effects of proglumide in rats. *J Pharmacol Exp Ther*. 1987 May;241(2):602-7.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA